Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VANCALLO: Oral Vancomycin for CDI Prevention in HSCT
NCT05256693Phase 3Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2022
- Primary completion
- Jun 2024
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Clostridium difficile infection (CDI) comparing Vancomycin Arm with Placebo Arm (2 arms). Primary endpoint: Proportion of patients with Clostridium difficile infection at 5 weeks. Status: unknown.
02
Drugs
vancomycin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT05256693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05256693.